Zynerba Pharmaceuticals - ZYNE Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZYNE shares.
View ZYNE analyst ratings or view top-rated stocks.

3 analysts have issued 1-year price targets for Zynerba Pharmaceuticals' shares. Their ZYNE share price forecasts range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 2,510.3% from the stock's current price.
View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts.

Zynerba Pharmaceuticals' stock was trading at $0.53 at the start of the year. Since then, ZYNE shares have decreased by 20.5% and is now trading at $0.4214.
View the best growth stocks for 2023 here.

Zynerba Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 238,000 shares, an increase of 30.8% from the February 28th total of 181,900 shares. Based on an average trading volume of 327,300 shares, the short-interest ratio is presently 0.7 days.
View Zynerba Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our ZYNE earnings forecast.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced its earnings results on Tuesday, March, 28th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06.

ETFs with the largest weight of Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock in their portfolio include Amplify Seymour Cannabis ETF (CNBS).ETFMG Alternative Harvest ETF (MJ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Zynerba Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include ETF Managers Group LLC (3.30%), Renaissance Technologies LLC (1.84%), Millennium Management LLC (1.22%), Geode Capital Management LLC (0.85%), Two Sigma Investments LP (0.16%) and Wells Fargo & Company MN (0.13%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher and Terri B Sebree.
View institutional ownership trends.

Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZYNE stock can currently be purchased for approximately $0.42.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $19.28 million. The company earns $-37,310,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com.